Table 1.
Single versus combination chemotherapy for recurrent ovarian cancer
| Study | N | Regimen | RR | Median PFS | OS |
|---|---|---|---|---|---|
| Bolis et al14 | 95 | Carboplatin | 56% | 12%, 3 years | 29%, 3 years |
| 95 | Carboplatin + epidoxorubicin | 62% | 25%, 3 years | 42%, 3 years | |
| NS | NS | NS | |||
| Cantú et al15 | 50 | Paclitaxel | 45% | 9 months | 26 months |
| 47 | CAP | 55% | 16 months | 35 months | |
| NS | P = 0.038 | P = 0.043 | |||
| Parmar et al11 | 392 | Carboplatin | 54% | 9 months | 24 months |
| ICON4/AGO-OVAR2.2 | 410 | Carboplatin + paclitaxel | 66% | 12 months | 29 months |
| P = 0.0004 | P = 0.02 | ||||
| HR 0.82 | |||||
| Gonzalez-Martin et al12 | 40 | Carboplatin | 50% | 8 months | 73 weeks |
| GEiCO | 41 | Carboplatin + paclitaxel | 75% | 11 months | Pending |
| P = 0.05 | P = 0.02 | ||||
| Pfisterer et al13 | 178 | Carboplatin | 31% | 5.8 months | 17.3 months |
| AGO-OVAR2.5 | 178 | Carboplatin + gemcitibine | 47% | 8.6 months | 18 months |
| GCiG | P = 0.0016 | P = 0.0031 | HR 0.96 | ||
| HR 0.76 | |||||
| Alberts et al16 | 30 | Carboplatin | 32% | 8 months | 18 months |
| 31 | Carboplatin + liposomal doxorubicin | 67% | 12 months | 26 months | |
| P = 0.02 | P = 0.02 | ||||
| Markman et al17 | 30 | Carboplatin | 28% | 8 months | 18 months |
| SWOG | 31 | Carboplatin + PLD | 59% | 12 months | 31 months |
| P = 0.2 | |||||
| Monk et al18 | PLD | 18.8% | 5.8 months | NS | |
| PLD + trabectedin | 27.6% | 7.3 months |
Abbreviations: HR, hazard ratio; N, number; NS, not significant; OS, overall survival; PFS, progression-free survival; PLD, pegylated liposomal doxorubicin; RR, relative risk.